Serum levels and pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients during chronic dosage
- PMID: 3089950
Serum levels and pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients during chronic dosage
Abstract
Ordinary and sustained-release lithium carbonate were administered at approximately equivalent daily dosage (1.5 and 1.8 g = 20.2 and 24.3 mmol ordinary and sustained-release respectively) in a crossover fashion to 5 manic patients. Actual and theoretical steady state serum levels of both preparations were determined. The sustained-release preparation gave observed serum levels that differed widely from predicted levels. Despite larger inter and intra-subject variations the serum levels at commencement and end of the sampling period were fairly constant. The results suggest that the wide individual variations in steady state profiles may be a consequence of the effect of normal physiological variables on drug absorption in the patient/sickness/diet combination of this study. Apparent erratic absorption in some patients, especially with the sustained-release preparation, indicates that great caution should be exercised in deciding when to monitor serum levels as a guide to adjusting dose. A justification is presented for morning sampling time as the most appropriate, regardless of the type of formulation used.
Similar articles
-
Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage.Eur J Clin Pharmacol. 1978 Dec 1;14(4):267-71. doi: 10.1007/BF00560460. Eur J Clin Pharmacol. 1978. PMID: 365541 Clinical Trial.
-
A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study.Clin Ter. 2002 Mar-Apr;153(2):107-15. Clin Ter. 2002. PMID: 12078335 Clinical Trial.
-
Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations.Int J Clin Pharmacol Ther Toxicol. 1986 May;24(5):240-5. Int J Clin Pharmacol Ther Toxicol. 1986. PMID: 3089949
-
What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?Bipolar Disord. 2008 Mar;10(2):231-7. doi: 10.1111/j.1399-5618.2007.00475.x. Bipolar Disord. 2008. PMID: 18271901 Review.
-
Key treatment studies of lithium in manic-depressive illness: efficacy and side effects.J Clin Psychiatry. 1998;59 Suppl 6:13-9; discussion 20. J Clin Psychiatry. 1998. PMID: 9674932 Review.
Cited by
-
Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.Eur J Clin Pharmacol. 2019 Apr;75(4):519-528. doi: 10.1007/s00228-018-2605-3. Epub 2018 Dec 15. Eur J Clin Pharmacol. 2019. PMID: 30554270